SCHEMBL18583178

SCHEMBL18583178

C=C/C=C\c1cccnc1C=C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 6/20 0.33
FGF23 Q9GZV9 1/20 0.33
TRIM24 O15164 1/20 0.33
TRIM33 Q9UPN9 1/20 0.33
KDM4E B2RXH2 4/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 3/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
ATM Q13315 1/20 0.31
GMNN O75496 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
HSP90AA1 P07900 1/20 0.31
MMP2 P08253 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
MMP9 P14780 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6516708 1.00 NFE2L2 (0.33) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL19540178 0.85 FGF23 (0.36) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL1396860 0.85 FGF23 (0.36) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL93457 0.81 ALDH1A1 (0.39) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL29554163 0.81 ALDH1A1 (0.39) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL782094 0.81 FGF23 (0.44) NFE2L2FGF23KDM4EALDH1A1MAPT
SCHEMBL25447214 0.81 FGF23 (0.33) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL12508936 0.81 FGF23 (0.36) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL19596554 0.81 FGF23 (0.33) NFE2L2FGF23TRIM24TRIM33KDM4E
SCHEMBL24601141 0.81 FGF23 (0.33) NFE2L2FGF23TRIM24TRIM33KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11396505-B2 Inhibitors of CaMKK2 and uses of same NEW YORK UNIVERSITY (US) 2022-07-26 US disclosed
US-20200369656-A1 INHIBITORS OF CAMKK2 AND USES OF SAME NEW YORK UNIVERSITY 2020-11-26 US disclosed
US-9763940-B2 Therapeutic use of P75 receptor antagonists SANOFI (FR) 2017-09-19 US disclosed
US-20170056400-A1 NOVEL THERAPEUTIC USE OF P75 RECEPTOR ANTAGONISTS SANOFI (FR) 2017-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396505-B2 Inhibitors of CaMKK2 and uses of same CAMKK2, CAMKK1, CAMK1 NFE2L2 822/4885FGF23 3996/4885TRIM24 2387/4885
US-20200369656-A1 INHIBITORS OF CAMKK2 AND USES OF SAME CAMKK2, CAMKK1, CAMK1 NFE2L2 822/4885FGF23 3996/4885TRIM24 2387/4885
US-20170056400-A1 NOVEL THERAPEUTIC USE OF P75 RECEPTOR ANTAGONISTS OPRL1, CHRNB2, OGFR NFE2L2 3282/4885FGF23 2222/4885TRIM24 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.